Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GCK | P35557 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27724831 | 0.98 | ABL1 (0.49) | ABL1RECQLNOS2FADS1CNR1 | |
| SCHEMBL1186026 | 0.87 | ABL1 (0.68) | ABL1CNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL1185611 | 0.83 | KMT2A (0.52) | RECQLKDM4EALDH1A1GAAALOX15 | |
| SCHEMBL7858859 | 0.83 | ALDH1A1 (0.53) | ABL1CNR1CNR2ALDH1A1ALOX15 | |
| SCHEMBL5371578 | 0.81 | CA1 (0.55) | KDM4EHPGDMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL7472823 | 0.81 | ALOX15 (0.48) | KDM4EALDH1A1GAAALOX15TSHR | |
| SCHEMBL2403279 | 0.81 | MAPT (0.47) | KDM4EALDH1A1GAAALOX15TSHR | |
| SCHEMBL267531 | 0.81 | ABL1 (0.74) | ABL1RECQLNOS2FADS1KDM4E | |
| SCHEMBL29009314 | 0.80 | RECQL (0.56) | ABL1RECQLNOS2FADS1KDM4E | |
| SCHEMBL26605192 | 0.80 | FADS1 (0.52) | ABL1RECQLNOS2FADS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| CN-102378753-B | Plasminogen activator-1 inhibitor | RENASCIENCE Co.,Ltd. (JP) | 2016-03-02 | — | — | CN | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| WO-2014069510-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2014-05-08 | — | — | WO | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| CN-102378753-A | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO LTD | 2012-03-14 | — | — | CN | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-0065864-B1 | ANTI-HYPERTENSIVE 1-SUBSTITUTED SPIRO (PIPERIDINE-OXOBENZOXAZINES) | SYNTEX (U.S.A.) INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0065864-A1 | Anti-hypertensive 1-substituted spiro (piperidine-oxobenzoxazines) | SYNTEX (U.S.A.) INC. (US) | 1982-12-01 | — | — | EP | disclosed |
| US-4349549-A | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s | SYNTEX (U.S.A.) INC. (US) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | ABL1 4431/4885RECQL 2914/4885NOS2 2767/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | ABL1 4431/4885RECQL 2914/4885NOS2 2767/4885 |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | HRH4, CLIC4, KRT18 | ABL1 1437/4885RECQL 3481/4885NOS2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.